Christopher Lieu, MD:Welcome to this contemporary Cancer Network™ K-Cast program titled “MRD and Decision-Making in Early Stage Colorectal Cancer.” I am Dr Christopher Lieu, from the University of Colorado in Denver. Our discussion is going to focus on optimizing the use of MRD [minimal residual disease] as a tool to guide decision-making in the adjuvant setting for patients at risk for recurrence. Welcome, and let’s begin.
Kristie L. Kahl:What is the role of tumor genomic profiling in colorectal cancer? Where are we, and how did we get here?